Neuroptis Biotech is a biotechnology company specialized in neurology and ophthalmology


Neuroptis Biotech aims at developing innovative treatments and protocols


Individuals working for Neuroptis Biotech have only two objectives:


  1. ‣ Bringing value to the shareholders


  1. ‣ Playing an active role for the globalized research community


Neuroptis Biotech has the unique chance to be working on three different projects which ranges from preclinical “proof of concept” study to exploratory phase IIa/b


Our targeted markets are all fast-growing segments such as dry-eye and/or covering unmet medical needs such as uveitis and cluster-headaches.


LEARN MORE ≫

 

About Neuroptis Biotech

LATEST NEWS

Marseille, May 21st,2012


Provence Technologies and Neuroptis Biotech partner to develop a new compound for treating dry eye syndrome


Provence Technologies to optimize and transfer the production process for ML7, Neuroptis Biotech’s dry eye drug candidate

Marseille, France, and Paris, France, 21 May, 2012 - Provence Technologies, a service provider of specialist fine chemistry, and Neuroptis Biotech, specializing in the discovery and development of innovative therapies in neurology and ophthalmology, announce today the further strengthening of their collaboration for transferring the chemical development of Neuroptis Biotech’s drug candidate, ML7, and producing the first GMP batches before the end of 2012.



READ MORE ≫